At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to … Read more
VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to … Read more
Henrik Watz, MD, PhD, has been named a 2024 Top Scholar by ScholarGPS, ranked #34 globally among chronic obstructive pulmonary disease (COPD) researchers over the past five years, and recognized among the top 0.5% of all researchers worldwide. Over the past year, Dr. Watz … Read more
Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma. Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. … Read more
When Velocity Clinical Research launched in December 2017, it had just two sites. Owned sites (SMOs) were the prevalent model at the time, and site networks were a collection of independent sites with a single point of contact. Velocity offered an alternative – a … Read more
Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s … Read more
In this article, Brandon Essink, MD, CPI, examines a critical challenge in clinical research: Principal Investigator attrition. Why do so many PIs leave research after just one trial? How can we support a sustainable, talented pipeline of investigators? What practical steps can Sponsors, CROs, … Read more
Paul Evans was featured in Applied Clinical Trials‘ latest article weighing in on the real-world implications of recent executive orders affecting DEI initiatives nationwide. In the piece, Paul underscores Velocity’s unwavering commitment to inclusive, patient-centered research environments, stating: “Velocity believes that clinical trials should … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of a new article reporting on a study that found prolonged elevation of hepatic biomarkers and fibrosis (scarring) scores is associated with a greater risk of negative clinical outcomes in patients with primary … Read more
Velocity is collaborating with Merck to enhance the way trial insights are shared within Merck and across Velocity sites worldwide. Through fast-response data exchange, we’ve developed the Velocity Insight Platform (VIP), a dynamic dashboard that provides actionable metrics to optimize site activities. A huge … Read more
Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.